Title :

Second allogeneic hematopoietic stem cell transplant: Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC).

Author(s) :

Yafour, Nabil [Auteur]
Couturier, Marie-Anne [Auteur]
Azarnoush, Saba [Auteur]
Girault, Stephane [Auteur]
Hermet, Eric [Auteur]
Masouridi-Levrat, Stavroula [Auteur]
Schmidt, Aline [Auteur]
Michallet, Mauricette [Auteur]
Etancelin, Pascaline [Auteur]
Guillaume, Thierry [Auteur]
Malard, Florent [Auteur]
Sirvent, Anne [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Poire, Xavier [Auteur]

Journal title :

Bulletin du cancer

Abbreviated title :

Bull. Cancer

Publication date :

2018-11-05

ISSN :

1769-6917
1769-6917

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Disease recurrence and graft dysfunction after allogeneic hematopoietic stem cell transplantation (allo-HSCT) currently remain among the major causes of treatment failure in malignant and non-malignant hematological ...
Show more >Disease recurrence and graft dysfunction after allogeneic hematopoietic stem cell transplantation (allo-HSCT) currently remain among the major causes of treatment failure in malignant and non-malignant hematological diseases. A second allo-HSCT is a valuable therapeutic option to salvage those situations. During the 8th annual harmonization workshops of the french Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines on feasibility, indications, donor choice and conditioning in the case of a second allo-HSCT. In case of relapse, a second allo-HSCT with reduced intensity or non-myeloablative conditioning is a reasonable option, particularly in patients with a good performance status (Karnofsky/Lansky>80%), low co-morbidity score (EBMT score</=3), a longer remission duration after the first allo-HSCT (>6 months), and who present low disease burden at the time of second allo-HSCT. Matched related donors tend to be associated with better outcomes. In the presence of graft dysfunction (primary and secondary graft rejection), an immunoablative conditioning regimen is recommended. A donor change remains a valid option, especially in the absence of graft-versus-host disease after the first allo-HSCT.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Inserm
Université de Lille
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Research team(s) :

Immunity, inflammation and fibrsis in auto and allo-reactivity

Submission date :

2019-03-01T14:07:49Z